Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Soleus sold 474,000 before the end of March

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on May 18, 2021 3:54pm

131 Views

Post# 33223744

RE:Soleus sold 474,000 before the end of March

As per their 13F yesterday filing Worth Venture partners increased their position from 146162 to 851413 shares and Morgan Stanley increased their position from 403870 shares to 703735 shares.

https://fintel.io/sob/us/thtx

SPCEO1 wrote: They still own nearly 7 million shares as of the end of March but did sell 474,000 between the offering and the end of March. Not sure what, if anything, that might mean but that is what Bloomberg is reporting.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing